AXT

AXT reported Q2 FY2026. EPS came in at $0.19 against a $0.07 consensus, beat by 171.4%. Revenue was $47.6M versus $34.1M expected, beat by 39.6%. Gross margin was 44.9%, up 1530 bps from last quarter.

AXT reported Q1 FY2026 results that exceeded street expectations, with revenue beating estimates by 2.7% and a significant improvement in gross margin. The company's financial trajectory and strategic initiatives indicate a positive outlook, despite ongoing challenges in the semiconductor industry.

The market was set up for a clean revenue recovery and got a Q4 revenue miss, but the investable surprise is that AXT now has visible Q1 shipment authorization, backlog above $60 million, and a management path to $35 million quarterly revenue by year-end. The variant view is that investors are likely over-penalizing the -8.5% Q4 miss and underpricing the operating leverage embedded in a 29.6% gross margin quarter and a stated route toward 35% gross margin at roughly $40 million quarterly revenue.

AXT missed the Street’s top line by -2.8%, but the economically relevant surprise was the EPS beat of +72.7% as indium phosphide snapped back and gross margin recovered to 22.3%. The market may be mispricing this as a one-quarter license catch-up; the better read is that Q3 reset the operating leverage framework, with Q4 guided above the Street-comparison actual and InP capacity now the binding variable.

AXT printed below Street on Q2 revenue and EPS, but the actionable point is that demand is not the binding constraint: management disclosed more than $10 million of customer orders waiting on permits while guiding Q3 revenue back to $19.0 million to $21.0 million. The market may be treating the quarter as another weak substrate print; the variant view is that the stock should trade on permit conversion and indium phosphide mix, not on Q2’s trough revenue.